IndustryCompany release

Aclaris reports early ATI-052 data in atopic dermatitis and asthma, backs Phase 2

🇺🇸 Aclaris Therapeutics, Inc. (ACRS) · Tue 27 Oct 2026

Aclaris says its anti-TSLP/anti-IL-4Rα bispecific cut EASI scores by 58% versus 13% on placebo at day 57 in atopic dermatitis, from small cohorts.

Aclaris Therapeutics presented primary analysis results on 27 October 2026 from a Phase 1b trial of ATI-052, an investigational bispecific antibody that targets both TSLP and IL-4Rα. The study enrolled patients with atopic dermatitis and with mild-to-moderate asthma.

In atopic dermatitis, patients given ATI-052 showed a 58% reduction in the Eczema Area and Severity Index (EASI) at day 57, compared with 13% for those on placebo. The company reported no cases of conjunctivitis in the study.

Aclaris says the findings support progressing the programme into Phase 2. The summary of the announcement does not give further detail on the asthma results, dosing or the safety profile beyond the absence of conjunctivitis.

The data carry clear limitations. They come from small per-protocol cohorts, and missing data were not imputed, which can affect how far the figures can be generalised. No regulatory action or agency interaction was announced.

What it means for your team

  • This is an early-phase, small-sample proof-of-concept readout; the efficacy figures should not be treated as confirmatory evidence.
  • The analysis was per-protocol without imputation of missing data, so the effect size may differ in larger, intention-to-treat analyses.
  • Pharmacovigilance teams may note the reported absence of conjunctivitis, an adverse event of interest for some therapies in this area, though the cohorts are too small to draw safety conclusions.
  • No regulatory filing or agency decision is attached to this news; Phase 2 design and any regulator feedback remain to be disclosed.

Company's press release (SEC filing): Aclaris Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Aclaris Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →